Kymera Therapeutics is a clinical-stage biopharmaceutical biotechnology company specializing in the discovery and development of novel small-molecule therapeutics using its proprietary targeted protein degradation platform. By harnessing the body's natural protein recycling machinery to selectively degrade disease-causing proteins, the enterprise focuses on addressing severe immunological conditions, chronic inflammatory diseases, and complex oncology indications that traditional pharmaceutical approaches have struggled to treat effectively.